Log in

Cellular Biomedicine Group Stock Forecast, Price & News

+0.13 (+0.70 %)
(As of 09/18/2020 12:00 AM ET)
Today's Range
Now: $18.70
50-Day Range
MA: $17.22
52-Week Range
Now: $18.70
Volume112,664 shs
Average Volume95,430 shs
Market Capitalization$363.40 million
P/E RatioN/A
Dividend YieldN/A
Cellular Biomedicine Group, Inc., a clinical stage biopharmaceutical company, develops therapies for cancer and degenerative diseases in Greater China. It focuses on developing and marketing cell-based therapies to treat various diseases, such as cancer and orthopedic diseases. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for treating a range of cancer indications comprising technologies in chimeric antigen receptor modified T cells (CAR-T), a genetically modified T-cell receptors (TCRs), and next generation neoantigen-reactive tumor infiltrating lymphocytes; and human adipose-derived mesenchymal progenitor cells for the treatment of joint diseases. The company's CAR-T products include CD20 for use in anti-tumor activities; CD22, a surface maker highly expressed in B cell malignancies in hairy cell leukemia; and B-cell maturation antigen therapies for treating refractory multiple myeloma in patients. It also develops NKG2D CAR therapies for use in NK cell signaling; alpha fetoprotein TCR-T therapies for treating hepatocellular carcinoma; tumor infiltrating lymphocyte therapies for treating immunogenic cancers; and knee osteoarthritis therapies, including AlloJoin therapy, which is in a Phase I clinical trial, as well as Re-Join that has completed the Phase IIb clinical trial. In addition, it engages in biopharmaceutical businesses, including research and development, technical support, technical service, and technology transfer activities in biomedical technology field; manufacturing non-food, pharmaceutical polypeptides, and medical devices; and the wholesale of cosmetics, sanitary products, and biological agents. The company has a strategic licensing and collaboration agreement with Novartis Pharma AG to manufacture and supply their CAR-T cell therapy Kymriah in China. Cellular Biomedicine Group, Inc. was incorporated in 2001 and is headquartered in New York, New York.
Read More
Cellular Biomedicine Group logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.66 out of 5 stars

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:CBMG



Sales & Book Value

Annual Sales$340,000.00
Book Value$2.89 per share


Net Income$-49,980,000.00


Market Cap$363.40 million
Next Earnings Date11/4/2020 (Estimated)
+0.13 (+0.70 %)
(As of 09/18/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CBMG News and Ratings via Email

Sign-up to receive the latest news and ratings for CBMG and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Cellular Biomedicine Group (NASDAQ:CBMG) Frequently Asked Questions

How has Cellular Biomedicine Group's stock been impacted by COVID-19?

Cellular Biomedicine Group's stock was trading at $14.49 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CBMG stock has increased by 29.1% and is now trading at $18.70.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Cellular Biomedicine Group?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cellular Biomedicine Group in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Cellular Biomedicine Group

When is Cellular Biomedicine Group's next earnings date?

Cellular Biomedicine Group is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Cellular Biomedicine Group

How were Cellular Biomedicine Group's earnings last quarter?

Cellular Biomedicine Group Inc (NASDAQ:CBMG) released its quarterly earnings results on Wednesday, August, 12th. The biotechnology company reported ($0.70) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.57) by $0.13.
View Cellular Biomedicine Group's earnings history

What price target have analysts set for CBMG?

2 Wall Street analysts have issued 1-year target prices for Cellular Biomedicine Group's shares. Their forecasts range from $19.00 to $19.00. On average, they expect Cellular Biomedicine Group's stock price to reach $19.00 in the next year. This suggests a possible upside of 1.6% from the stock's current price.
View analysts' price targets for Cellular Biomedicine Group

Are investors shorting Cellular Biomedicine Group?

Cellular Biomedicine Group saw a increase in short interest in August. As of August 31st, there was short interest totaling 430,800 shares, an increase of 10.7% from the August 15th total of 389,200 shares. Based on an average daily trading volume, of 141,500 shares, the short-interest ratio is presently 3.0 days. Currently, 3.8% of the company's stock are sold short.
View Cellular Biomedicine Group's Short Interest

Who are some of Cellular Biomedicine Group's key competitors?

What other stocks do shareholders of Cellular Biomedicine Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cellular Biomedicine Group investors own include Crispr Therapeutics (CRSP), Aduro BioTech (ADRO), Amarin (AMRN), Anavex Life Sciences (AVXL), Adaptimmune Therapeutics (ADAP), Exelixis (EXEL), Fate Therapeutics (FATE), ImmunoGen (IMGN), AT&T (T) and Iovance Biotherapeutics (IOVA).

Who are Cellular Biomedicine Group's key executives?

Cellular Biomedicine Group's management team includes the following people:
  • Mr. Bizuo Liu, CEO, CFO & Director (Age 54)
  • Dr. Yihong Yao, Chief Scientific Officer (Age 51)
  • Mr. Andrew K. Chan, Chief Legal Officer, Gen. Counsel, Sr. VP of Corp. Bus. Devel. & Sec. (Age 61)
  • Dr. Li Zhang, Chief Production Officer
  • Derrick C. Li, Head of Strategy & Investor Relations

What is Cellular Biomedicine Group's stock symbol?

Cellular Biomedicine Group trades on the NASDAQ under the ticker symbol "CBMG."

Who are Cellular Biomedicine Group's major shareholders?

Cellular Biomedicine Group's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Platinum Investment Management Ltd. (0.70%), Russell Investments Group Ltd. (0.69%), Man Group plc (0.56%), Bessemer Group Inc. (0.25%), Bank of New York Mellon Corp (0.19%) and Charles Schwab Investment Management Inc. (0.15%).
View institutional ownership trends for Cellular Biomedicine Group

Which institutional investors are selling Cellular Biomedicine Group stock?

CBMG stock was sold by a variety of institutional investors in the last quarter, including Platinum Investment Management Ltd., Man Group plc, Vident Investment Advisory LLC, and UBS Group AG.
View insider buying and selling activity for Cellular Biomedicine Group

Which institutional investors are buying Cellular Biomedicine Group stock?

CBMG stock was bought by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Bessemer Group Inc., SG Americas Securities LLC, Bank of America Corp DE, Bank of New York Mellon Corp, Charles Schwab Investment Management Inc., and California Public Employees Retirement System.
View insider buying and selling activity for Cellular Biomedicine Group

How do I buy shares of Cellular Biomedicine Group?

Shares of CBMG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Cellular Biomedicine Group's stock price today?

One share of CBMG stock can currently be purchased for approximately $18.70.

How big of a company is Cellular Biomedicine Group?

Cellular Biomedicine Group has a market capitalization of $363.40 million and generates $340,000.00 in revenue each year. The biotechnology company earns $-49,980,000.00 in net income (profit) each year or ($2.63) on an earnings per share basis. Cellular Biomedicine Group employs 193 workers across the globe.

What is Cellular Biomedicine Group's official website?

The official website for Cellular Biomedicine Group is www.cellbiomedgroup.com.

How can I contact Cellular Biomedicine Group?

Cellular Biomedicine Group's mailing address is 1345 AVENUE OF AMERICAS 15TH FLOOR, NEW YORK NY, 10105. The biotechnology company can be reached via phone at 347-905-5663 or via email at [email protected]

This page was last updated on 9/19/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.